Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Acute Myeloid Leukemia | Unmet Need | First-Line Intensive-Induction-Eligible | US/FR/DEU/UK | 2023

Login to access report north_east
Contact sales account_box

Acute myeloid leukemia (AML) is the most common acute leukemia in adults, originating from mutant myeloid precursor cells. Presently, the AML drug market is dominated by chemotherapy backbones, but recent drug approvals suggest a shift toward targeted agents. Approximately 70% of patients treated with cytotoxic chemotherapy achieve complete remission. Nevertheless, the five-year relative survival rate is only 30.5%. In this report, we focus on the unmet need in the first-line treatment of intensive-induction-eligible AML. These patients currently receive cytotoxic chemotherapy, with or without biomarker-driven targeted therapies (such as Mylotarg and Rydapt) or the topoisomerase II inhibitor Vyxeos.

QUESTIONS ANSWERED

  • What treatment drivers and goals are most important to surveyed hematologist-oncologists when selecting a first-line therapy for intensive-induction-eligible AML?
  • How do key currently available regimens, including Vyxeos or Rydapt in combination with intensive chemotherapy, perform in terms of key attributes?
  • What are the greatest unmet needs and most attractive opportunities in the first-line treatment of intensive-induction-eligible AML?
  • What tradeoffs are surveyed hematologist-oncologists willing to make for new and emerging therapies to treat this subpopulation of AML?

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.

Markets covered: United States, France, Germany, United Kingdom

Primary research: Survey of 62 U.S. and 31 European hematologist-oncologists fielded in December 2022.

Key companies: Pfizer, Novartis, Jazz Pharmaceuticals

Key drugs: Mylotarg, Rydapt, Vyxeos, cytarabine, daunorubicin, fludarabine, G-CSF, and idarubicin

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east